Loading
A phase 1/2 trial of Cemiplimab in ovarian cancer and endometrial cancer, run by Regeneron Pharmaceuticals, now recruiting.
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab is a phase 1/2 interventional study registered as NCT04590326 by Regeneron Pharmaceuticals, with 612 participants planned, started 2020-12-08 and due to reach its primary completion in 2027-03-25. Interventions recorded: REGN5668, Cemiplimab, Ubamatamab, Sarilumab, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]. Conditions listed: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer. No results are recorded here; the registry entry is the source.
Shares Ubamatamab, Regeneron, Cemiplimab, Endometrial cancer.
Shares Ubamatamab, Regeneron, Cemiplimab, Ovarian cancer.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.